Patient Education

Peptide Therapy and Lab Work: What Blood Tests Should You Get?

Lab work is one of the features that separates responsible peptide therapy from the do-it-yourself version. If you're considering a clinical peptide protocol, your provider should order baseline bloodwork before you start — and repeat relevant panels at defined intervals during treatment. The specific tests depend on which compounds are being prescribed, but some core panels apply to nearly every protocol. Here's what to expect, what each test tells your provider, and why skipping this step is a problem.

Why Lab Work Matters

The therapeutic peptides used in clinical settings are biologically active compounds that affect hormonal signaling, metabolism, immune function, and tissue repair. Some of these effects are what you're seeking. Others are side effects or signals that a protocol needs adjustment.

Without baseline labs, there is no way to:

Identify contraindications that could make a therapy unsafe for you specifically
Know whether you're actually deficient in the thing a therapy is meant to support
Measure whether the treatment is working
Detect adverse changes before they become clinical problems

A provider who doesn't require labs before prescribing systemic peptides is making clinical decisions without the information needed to make them well.

Core Labs for Most Peptide Protocols

Comprehensive Metabolic Panel (CMP)

A standard panel covering kidney function (creatinine, BUN), liver function (ALT, AST, alkaline phosphatase, bilirubin), electrolytes, and blood glucose. This is baseline clinical data that any responsible prescriber should have before starting any new therapy. For peptide protocols that affect metabolic function, it is particularly relevant.

Complete Blood Count (CBC)

Measures red blood cells, white blood cells, and platelets. Relevant for establishing immune baseline (particularly for immunomodulatory peptides like thymosin alpha-1) and detecting any pre-existing hematologic conditions.

HbA1c and Fasting Glucose

Critical for GLP-1 protocols and growth hormone secretagogues, both of which affect insulin sensitivity and blood sugar regulation. HbA1c gives a 90-day average of blood glucose control. A provider prescribing ipamorelin or semaglutide without knowing your baseline blood sugar is missing essential data.

Lipid Panel

Total cholesterol, LDL, HDL, and triglycerides. Growth hormone has effects on lipid metabolism, and GLP-1 peptides affect cardiovascular risk factors. Baseline lipid status provides context for interpreting changes during treatment.

Thyroid Function (TSH, Free T4, Free T3)

Thyroid dysfunction can present with many of the same symptoms that prompt interest in peptide therapy — fatigue, body composition changes, poor recovery, mood changes. Ruling out or identifying thyroid issues before starting peptide protocols is important both for accurate attribution of symptoms and because some peptides may affect thyroid function.

Labs Specific to Growth Hormone Secretagogue Protocols

If you're starting ipamorelin, sermorelin, CJC-1295, or another growth hormone secretagogue, IGF-1 is the critical marker.

IGF-1 (Insulin-Like Growth Factor 1)

IGF-1 is the primary downstream mediator of growth hormone's effects on tissues. Because growth hormone is released in pulses and is difficult to measure directly, IGF-1 — which reflects overall growth hormone activity over a longer timeframe — is the standard clinical proxy.

Baseline IGF-1 establishes whether you are genuinely growth hormone deficient or in the lower range of normal, which informs both the rationale for treatment and the target during therapy. IGF-1 is also the marker most closely associated with safety concerns: chronically elevated IGF-1 is linked to increased cancer risk, making it the key variable to monitor during growth hormone secretagogue therapy.

Most providers prescribing growth hormone secretagogues target IGF-1 within the normal physiological range for age rather than aiming for peak youthful levels. Regular monitoring — typically at 4-6 weeks after initiating a protocol, then quarterly or semi-annually during maintenance — is standard practice.

IGFBP-3 (Insulin-Like Growth Factor Binding Protein 3)

Often ordered alongside IGF-1 for a more complete picture of growth hormone activity. Less commonly required as a standalone but useful in certain clinical contexts.

Labs for Immune-Modulating Peptides

Thymosin Alpha-1 protocols:

Patients starting thymosin alpha-1 benefit from a baseline immune panel including:

CD4/CD8 T-cell counts (where clinically indicated)
Natural killer (NK) cell activity (in specialized contexts)
CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) as markers of systemic inflammation

For most patients, the standard CBC with differential provides adequate immune baseline. More comprehensive immune panels are appropriate for patients with documented immune deficiency or specific immune conditions.

Labs for Metabolic and GLP-1 Protocols

GLP-1 receptor agonist protocols (semaglutide, tirzepatide):

In addition to the core metabolic panel:

HbA1c and fasting glucose (essential — see above)
Lipid panel
Kidney function (GLP-1 drugs affect renal handling in ways relevant to monitoring)
Amylase and lipase — GLP-1 drugs carry a class warning for pancreatitis; baseline pancreatic enzyme levels are appropriate
Calcitonin — GLP-1 drugs carry a theoretical risk for medullary thyroid cancer (based on rodent data); calcitonin screening is recommended in patients with personal or family history of thyroid cancer or MEN 2

Labs for BPC-157 and Tissue Repair Peptides

BPC-157 does not have specific biomarker monitoring requirements in the way that growth hormone secretagogues do. A standard baseline metabolic panel is appropriate. For patients using BPC-157 for specific conditions — gut permeability, inflammatory bowel disease — disease-specific markers (CRP, fecal calprotectin, zonulin where available) can help track therapeutic response.

How Often Should Labs Be Repeated?

The monitoring schedule depends on the protocol, but a general framework:

Initiation (baseline): Full panel before starting any protocol

4-6 weeks after starting: Key markers for the specific protocol (IGF-1 for GH secretagogues; HbA1c/metabolic panel for GLP-1 therapy)

3 months: Comprehensive review and dose adjustment decision point

Every 6 months during maintenance: Full panel to ensure continued safety and assess ongoing response

Providers may adjust this schedule based on individual circumstances. The point is that labs should not be a one-time event.

What to Do With Your Results

Your provider should review lab results with you in the context of your symptoms and goals, not just flag anything outside the reference range. Reference ranges are population averages; optimal ranges for your health goals may differ. A provider who simply emails a lab report without discussion is not providing adequate follow-up.

Questions worth asking when reviewing results:

Is my IGF-1 in a range that justifies or supports this therapy?
Has my blood glucose or lipid profile changed in a way that warrants protocol adjustment?
Are there any values that would prompt you to change or stop this therapy?

Frequently Asked Questions

Do I need labs if I'm just starting a low-dose protocol?

Yes. Even low-dose protocols affecting systemic hormonal signaling should start with baseline labs. The purpose of baseline labs is not just to monitor for dose-related effects but to identify contraindications and establish a reference point.

Can I order my own labs without a provider?

In many states, you can order your own labs through direct-to-consumer services like LabCorp Patient or Quest MyQuest. This can be useful for establishing a baseline or monitoring if you're in a gap between provider visits. But it doesn't substitute for provider interpretation in the context of a treatment plan.

What if my provider won't order labs?

If a provider is unwilling to order baseline labs for a systemic peptide protocol, that is a significant concern. Consider it a red flag and seek care elsewhere.

How much does the typical lab panel cost?

Out-of-pocket cost for a comprehensive baseline panel (CMP, CBC, HbA1c, lipid panel, thyroid, IGF-1) typically runs $150-350 depending on the lab and whether you have insurance. Some providers include lab costs in their consultation fees; others order through your insurance with potential cost-sharing.

Does my primary care doctor need to know about my peptide therapy labs?

It is generally good practice to share lab results with your primary care provider so they have a complete picture of your health. Some markers that change with peptide therapy — IGF-1, blood glucose, lipids — are relevant to your overall health management.

Sources

This content is for educational purposes only and does not constitute medical advice. Peptide therapies should only be pursued under the supervision of a licensed healthcare provider. Amino Clinic recommends consulting with your physician before starting any new therapy.